Official Title: Effectiveness of olaparib plus trastuzumab in HER2-positive BRCA-mutated or Homologous Recombination Deficiency (HRD) advanced breast cancer patients.
The OPHELIA study is a multicenter, open-label, single-arm, two cohorts, Simon’s Two-Stage minimax design, phase II clinical trial.
The primary objective of this trial is to assess the efficacy – as determined by the Overall Response Rate (ORR) and Progression-free Survival (PFS) based on RECIST v.1.1 – of olaparib in combination with trastuzumab in patients with HER2-positive, germinal BRCA1/2 mutated ABC.
OPHELIA at clinicaltrials.gov
ESMO 2019 OPHELIA Poster – List of COIs
ESMO 2019 Poster